The end of July saw a series of investment and related job creation announcements in the Irish pharma industry.
Hot on the heels of Bausch + Lomb’s announcement of 130 new jobs in Waterford, there have been three other companies announcing investment in the sector…
To see these jobs as soon as they’re advertised, be sure to keep an eye on Ireland’s Largest Pharmaceutical Jobs Board.
Repligen Corporation create 130 jobs in Waterford
The global life science company announced plans to expand its Waterford manufacturing facility. The new facility will become the company’s “Centre of Excellence for single-use consumable products used in bioprocessing applications” and is expected to bring 130 new jobs over the next two-and-a-half years.
James Bylund, Senior Vice-President, Global Operations and Information Technology at Repligen, told IDA Ireland:
We are thrilled to continue the collaboration with the Irish Government and the IDA that was initiated by the ARTeSYN team. This buildout is an important step in expanding our capacity and establishing dual manufacturing sites for key single-use consumable products used in manufacture of biological drugs.
Repligen produce single-use bioprocessing technologies with a focus of increasing efficiencies in the process of manufacturing biological drugs. They acquired the Waterford site from ARTeSYN BioSolutions in December 2020.
Charles River announce €8m expansion of Mayo site, bringing up to 90 new jobs
The contract research organisation is investing in their biologics testing site in Ballina, to “facilitate batch release testing for COVID-19 vaccines” as the company continues its strategic partnership with AstraZeneca.
The investment is expected to lead to 1,500m2 of additional lab space and bring up to 90 new jobs over the next three years.
Liam McHale, site director for Charles River Ballina told IDA Ireland:
We are incredibly proud of the transformational changes we have implemented on site and the role that Charles River has played in supporting the safe and timely rollout of AstraZeneca’s COVID-19 vaccine. Throughout the pandemic, our site remained fully operational while keeping our employees safe and having a positive impact on human health. Our expanded facility will provide us with the increased capacity needed to continue the essential services we provide to our clients.
Abbott confirm €37.8m R&D investment in Tipperary
The company’s cardiovascular R&D centre within its Vascular Devices site in Clonmel is receiving the investment for a programme of “discovery, innovation and development of a number of projects, including next generation drug eluting stents, as well as coronary and endovascular balloon technologies”.
The announcement comes as Abbot celebrate 75 years of operations in Ireland, where the company now employ almost 4,000 staff across nine sites.
Deirdre Mullins, site director, Abbott in Clonmel told IDA Ireland:
“Our market leading XIENCE stents were developed in Clonmel and today’s announcement places us at the vanguard of Abbott’s global research efforts in cardiovascular treatments. We are very proud that the life changing technologies we design and manufacture in Clonmel are saving lives in Ireland and across the world.”